Lupin intros generic Lodosyn
Lupin has launched its generic of Lodosyn (carbidopa) tablets. The company had previously received approval from the Food and Drug Administration for the generic, which is indicated to treat symptoms associated with Parkinson’s disease alongside carbidopa-levodopa or levodopa.
Lupin’s generic Lodosyn will be available in 25-mg dosage strength. The product has a market size of roughly $17.4 million for the 12 months ended January 2018, according to IQVIA data.
Mayne Pharma’s generic Quartette launches
Mayne Pharma has introduced its generic Quartette. The contraceptive product is a combination of levonorgestrel and ethinyl estradiol tablets, 0.15mg/0.02mg; 0.15mg/0.025mg; 0.15mg/0.03mg and ethinyl estradiol tablets, 0.01mg, and adds to the company’s already existing 22 marketed women’s health products.
“Mayne Pharma is the second largest supplier of oral contraceptive products in the United States and continues to invest in growing its pipeline of women’s health products with high value, complex formulations such as generic NuvaRing, an intravaginal hormonal contraceptive delivery device which recently was accepted for filing by the FDA,” Mayne Pharma CEO Scott Richards said
The Adelaide, Australia-based company’s generic Quartette launches into a market that had estimated sales of roughly $10 million for the 12 months ended January 2018.
AmerisourceBergen Foundation grant funds substance abuse symposium
AmerisourceBergen’s charitable arm and Thomas Jefferson University are teaming to fight opioid abuse and misuse in the Philadelphia area. The AmerisourceBergen Foundation has awarded the university a $50,000 grant to sponsor its second annual Substance Use Disorders Symposium.
The symposium, set to take place on May 29 at the university’s Center City campus, will bring lawmakers, community representatives and lawmakers to talk about a coordinated approach to curb the opioid crisis across the city. Speakers will focus on such topics as medication-assisted treatment, pain management for patients in recovery and management of opioid overdose, as well as patient perspectives on addiction and recovery.
“We are delighted that the AmerisourceBergen Foundation has offered to support Jefferson’s opioid crisis educational conference, which will shed light on this devastating public health emergency,” chair of the Thomas Jefferson University Dept. of Emergency Medicine Theodore Christopher said. “In addition to prescribing less opioid medication to all patients, physicians need to learn about the processes and logistics around treating opioid-addicted patients, and referring them to appropriate facilities and providers in the city.”
This partnership is the latest of the AmerisourceBergen Foundation’s collaboration with the university to help meet community needs. It donated $250,000 for a pharmacy at Project HOME’s Stephen Klein Wellness Center in North Philadelphia, and in 2017, the foundation gave $50,000 to the university’s Sidney Kimmel Cancer Center to support its cancer support and welcome center.
“As leaders in this region and across the nation organize efforts to combat opioid abuse, we — at AmerisourceBergen — aim to provide them with the resources needed to prevent misuse and drive sustained change,” said Gina Clark, AmerisourceBergen Foundation president and executive vice president and chief communications and administration officer at AmerisourceBergen. “At AmerisourceBergen, we are united in our responsibility to create healthier futures. Through our work with Thomas Jefferson University, we hope to convene leaders within the healthcare industry and community to identify best practices and develop action plans to combat opioid abuse.”
For more information about the symposium, click here.